SupplementCaP CURE Initiatives and ProjectsHoward R SouleProstate cancerProstate-specific antigenCaP CURE
SupplementA Multidisciplinary Approach to the Management of Hormone-Refractory Prostate CancerSamir S TanejaProstate cancerAndrogen-insensitiveHormone-refractoryMultidisciplinary
SupplementInnovative Therapies for Prostate Cancer TreatmentSamira SyedAnthony TolcherDocetaxelHormone-refractory prostate cancerAntisense oligonucleotides
SupplementA New Paradigm for the Treatment of High-Risk Prostate Cancer: Radiosensitization with DocetaxelParvesh KumarProstate cancerDocetaxelThree-dimensional conformal radiation therapyRadiosensitization
SupplementDocetaxel and Thalidomide as a Treatment Option for Androgen-Independent, Nonmetastatic Prostate CancerWilliam D FiggGregory D LeonardPhilip M ArlenJames L GulleyWilliam L DahutDocetaxelAndrogen-independent prostate cancerThalidomidePalliative
SupplementA Multi-Institutional Pilot Study of Adjuvant Docetaxel for Patients with Prostate Cancer at High Risk for Relapse After Radical ProstatectomyMario A EisenbergerHormone-refractory prostate cancerAdjuvant chemotherapyRadical
SupplementE-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer...Robert DreicerMichael CarducciProstate cancerDocetaxelEstramustineKetoconazole
SupplementRationale for the Radiation Therapy Oncology Group Study RTOG P-0014Howard M SandlerKenneth J PientaProstate cancerChemotherapyAndrogen ablationClinical trialsHormone-refractory disease
SupplementA New Formulation of Calcitriol (DN-101) for High-Dose Pulse Administration in Prostate Cancer TherapyWilliam David HennerTomasz M BeerHypercalcemiaCalcitriolAndrogen-independent prostate cancerHigh-dose
SupplementNeoadjuvant Therapy for Prostate Cancer: An Oncologist's PerspectiveElizabeth C KentMaha HA HussainProstate cancerChemotherapyRadical prostatectomyRadiotherapyHormonal therapyNeoadjuvant therapy
SupplementInitial Experience with Single-Agent Docetaxel as Neoadjuvant Therapy in Men with Locally Advanced Prostate CancerEric A KleinRobert DreicerLocally advanced prostate cancerRadical prostatectomyNeoadjuvant
SupplementDocetaxel for the Treatment of Hormone-Refractory Prostate CancerDaniel P PetrylakChemotherapyProstate-specific antigenDocetaxelHormone-refractory prostate cancerMicrotubule
SupplementBiochemical (Prostate-Specific Antigen) Relapse: An Oncologist's PerspectiveMary-Ellen TaplinProstate cancerProstate-specific antigenAdjuvantBiochemical relapse